Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
Results Demonstrate Safety and Efficacy of First-in-Class Neurally
09-Sep-2008 -
CoLucid Pharmaceuticals, Inc., announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), which ...
dosing
migraine
reductions